Investigating how EHD1 affects inflammation in heart disease
Official title: EHD1-mediated Inflammation and Resolution in Atherosclerosis
Funded at Icahn School of Medicine at Mount Sinai · NIH-11063966 · Data updated 2026-11-12
This study is looking at a protein called EHD1 to see how it affects inflammation in heart disease, with the hope of finding new ways to help people with this condition feel better and heal faster.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $633,171 |
| NIH project number | 5R01HL167107-03 |
| Project ID | NIH-11063966 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with atherosclerotic cardiovascular disease who experience ongoing inflammation despite standard lipid-lowering therapies.
✕Less likely to help
Patients without atherosclerotic cardiovascular disease or those whose condition is unrelated to inflammation may not benefit from this research.
What this research studies
This research focuses on understanding the role of EHD1, a protein involved in cellular processes, in the inflammation associated with atherosclerotic cardiovascular disease (CVD). By examining how EHD1 influences macrophage function and inflammation resolution, the study aims to identify new therapeutic targets that could improve treatment outcomes for patients with heart disease. The research utilizes advanced techniques like single-cell RNA sequencing to analyze macrophage populations in atherosclerotic plaques from both humans and mice. This approach may lead to innovative strategies to enhance tissue repair and reduce inflammation in affected individuals.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce inflammation and improve heart health for patients with atherosclerosis.
How similar studies have gone: Other research has shown promising results in targeting inflammation in cardiovascular disease, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Cai, Bishuang — Icahn School of Medicine at Mount Sinai
- Study coordinator: Cai, Bishuang
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
PFAS may speed up artery disease by changing bile acids
Aims to see if PFAS chemicals make cholesterol rise and arteries more likely to harden, using a human-similar mouse model to understand how this could affect people.
-
IgE antibodies to alpha-gal and heart disease in mice and people
A study to understand how specific IgE antibodies against alpha-gal might influence the development and severity of atherosclerosis in humans and mouse models.
-
Fibroblast Growth Factor 1 to Reduce High Lipids and Plaque in Adults with Diabetes
A new approach uses a modified FGF1 protein to lower bad cholesterol and prevent artery plaque buildup in adults with Type 2 diabetes, aiming for safer and more effective treatment.
-
Atherosclerosis in cocaine addiction: imaging risk with PET/MR
This project uses PET/MR imaging to look for early artery disease in people with cocaine use disorder to help prevent strokes or other brain injuries.
-
How low blood flow after brain artery narrowing affects the vessel lining
This work looks at whether areas of low blood flow downstream of narrowed brain arteries cause vessel lining damage and raise the chance of another stroke, for people with intracranial artery narrowing.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.